UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRANT
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE
ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-53230

PEPTIDE TECHNOLOGIES, INC.

601 Union Street, Two Union Square, 42nd Floor, Seattle, WA 98101
(Address of Principal Executive Offices)

(206) 452-3995
(Telephone number, including area code)

Common Stock
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty
to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the
appropriate rule provision(s) relied upon
to terminate or suspend the duty to file

                                    reports:

Rule 12g-4(a)1 [X]                                      Rule 12h-3(b)(1)(I) [_]
Rule 12g-4(a)2 [_]                                      Rule 12h-3(b)(1)(ii) [_]
Rule 15d-6 [_]                                          Rule 15-15D [_]

Approximate number of holders of record as of the certification or notice date:
100

Pursuant to the requirements of the Securities Exchange Act of 1934 Peptide Technologies has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.


Date: March 10, 2015                By: /s/ Baxter Koehn
                                        ----------------------------------------
                                        Baxter Koehn, CFO

Instruction: This form is required by Rules 12g-4, 12h-3, and 15d-6 of the General Rules and Regulations under the Securities Exchange Act of 1934. The Registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel, or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.